Registration Options

Activity Dates: 04/09/2024 - 04/09/2027

AAPP 2024 registration is closed.

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

The morbidity and mortality risks of untreated opioid use disorder (OUD) continue to grow. Introduction of new substances (e.g. xylazine, fentanyl, kratom) into the supply chain complicates our traditional conceptualization of OUD management. Clinicians need to be aware of how often these substances may be used in their patient population, recognize their unique presentations, and effectively treat patients so they may achieve recovery. Participants will learn to provide education to patients and other healthcare professionals about the dangers of these substances and manage patients who use these products.

Consider making this session part of your BPS Continuing Professional Development plan! Please refer to the BPS Psychiatric Pharmacy Content Outline to see how this activity may align.

Course Requirements

To receive ACPE credit for this session, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information and Disclosures

Steven W. Shoyer, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Identify geographical trends and prevalence of xylazine, fentanyl, and kratom use.
  2. Describe the pharmacologic profile and potency characteristics of xylazine, fentanyl, and kratom.
  3. Discuss the complications each substance may pose to traditional management of opioid overdose, withdrawal, and opioid use disorder treatment.

Continuing Education Credit and Disclosures

Activity Dates: 04/09/2024 - 04/09/2027
ACPE Contact Hours: 1
ACPE Number: 0284-0000-24-030-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.